Accelerating the Genetic Revolution

Neurological Disorders
Muscular Dystrophies
Ocular Diseases
Oncology

A new class of synthetic medicines with the potential of limitless impact

We are at a fundamental inflection point in the history of the pharmaceutical industry where, as a result of the Human Genome Project, we now have the ability to leverage nature’s own information encoding system (the genetic code) to “digitally” encode our drugs so as to target a precise gene that is malfunctioning and neutralize the disease process at its root cause.

As every human disease has genetic drivers, our vision is to dramatically reduce the suffering and death attributable to innumerable diseases across the globe with our first-in-class technology platform.

The therapies we are creating are analogous to heat-seeking missiles in that they are highly specific to only the target gene and promise easy to take and well tolerated medicines.

Technology

The advantages of the NeuBase PATrOL™ platform enable the company to cohesively develop therapies for a wide range of diseases including single-gene disorders, cancers and common diseases

NeuBase is first addressing Huntington’s disease and myotonic dystrophy

Read More

The NeuBase technology has several advantages over other precision genetic medicines

Sd

Scalable & Modular Development

Pre-organized rigid synthetic scaffold increases precision of engagement with target and toolkit of engineered nucleobases allow drugs to be quickly snapped together for many targets

Ts

Targeting Structures

Higher specificity for mutant over wild type genes, allowing for fewer off-target effects and more effective deactivation of disease-causing genes at the DNA and RNA levels

BrOD

Broad Organ Distribution

Modular delivery technologies enable targeting a variety of organ systems

Ni

No Immune Response

Therapies do not cause an immune response when systemically administered, enabling us to develop solutions for pre-symptomatic individuals who are gene mutation positive

NeuBase Therapeutics Announces Appointment of Curt Bradshaw, Ph.D. as Chief Scientific Officer

PITTSBURGH, Dec. 02, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, today announced the appointment of Curt Bradshaw, Ph.D., as its new Chief Scientific Officer. Dr. Bradshaw is a proven drug developer in the field of precision genetic medicines, coming to NeuBase from his most recent role as Chief Scientific Officer at Arrowhead Pharmaceuticals. In his new role, Dr. Bradshaw will be responsible for leading and expanding NeuBase’s PATrOL-enabled anti-gene pipeline and will serve as a key member of its executive management team.

Read More

NeuBase Therapeutics to Participate in Upcoming Investor Conferences

PITTSBURGH, Nov. 23, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will participate in a virtual fireside chat at the 32nd Annual Piper Sandler Virtual Healthcare Conference taking place between December 1-3, 2020, as well as in a panel discussion at the 3rd Annual Evercore ISI HealthCONx Conference, which is also being held from December 1-3, 2020.

Read More

NeuBase Therapeutics Announces Addition of Eriks Rozners, Ph.D. and Randy Davis, MBA to Scientific Advisory Board

PITTSBURGH, Nov. 17, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, today announced the addition of Eriks Rozners, Ph.D. and Randy Davis, MBA to its scientific advisory board (SAB). Dr. Rozners, an expert in nucleic acid biochemistry, and Mr. Davis, a biotechnology industry veteran, bring extensive experience to NeuBase.

Read More

NeuBase Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference on Tuesday, November 17

PITTSBURGH, Nov. 10, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will present a corporate overview at the Stifel 2020 Virtual Healthcare Conference being held on November 16 - 18.

Read More

close

Covid-19 Update

Read our statement related to operations during COVID-19